Methodist Health System
Dallas, Texas, 75203, United States
Completed
NCT Number: NCT05117190
Human Composite Facial Allotransplantation
Allotransplantation of maxillofacial of subject with severe facial deformities due to traumatic events.
Completed
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year–70 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Not applicable
Primary location
About this study
A facial transplantation is a highly dynamic, prolonged operation requiring teams communicating seamlessly through its duration. This is similar to complex solid organ transplant teams at Methodist Transplant Institute. The Institute's clinical experience in management of complex facial defects and deformities along with the personnel and infrastructure at Methodist Dallas transplant institute would help develop a center for Facial Allotransplantation. The team experience, true collaboration, creativity and a unique approach to each patient would help provide the optimal care and reconstruction for the face allotransplant patient both before and after surgery.
The purpose of this study is centered on the advancement of a safe and effective procedure for Facial Allotransplantation at Methodist Hospital Medical Center at Dallas. Composite tissue allotransplantation for facial reconstruction is in its infancy as liver transplantation was 30 years ago when the first liver transplant was completed in Texas. This study will establish Methodist Hospital System as a center for Facial Allotransplantation for reconstruction of extensive facial defects resulting in functional loss and poor quality of life.
Patient participation post transplantation will either be for life, or failure of the composite tissue allograft. Patient enrollment will be initiated immediately after the IRB approval. The enrollment period will be completed after the patient receives the final transplant, and the study will be completed at 24 months after the final transplant. However, all patients enrolled into the study will have lifelong follow up with immunosuppressive management, psychological support, and evaluation of functional recovery per protocol.
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Between ages 18-70 years
- Must be willing to undergo major facial reconstruction
- Be able to understand the pre and post-transplantation evaluation, physical therapy, and follow up procedures
- Conventional reconstruction deemed unsatisfactory
Exclusion criteria
- Medically unable to provide consent
- Active infections such as Human Immunodeficiency Virus, mycobacteria, hepatitis B, and hepatitis C
- Recent history of alcohol or IV drug or chemical dependency
- Psychiatric evaluation that indicate mental instability or non-compliance
- Cognitively impaired and Terminally ill
- Women of child bearing age with intent to conceive, pregnant or lactating
- Unable to receive immunosuppression after transplantation because of either geographic or financial limitations
- End stage organ disease (renal failure, Congestive Heart Failure (CHF), Chronic Obstructive Pulmonary Disease (COPD), etc.)
- Chronic infections such as osteomyelitis
Treatment and study plan
Facial Allotransplantation
ProcedurePrimary outcomes
-
Modified Facial Clinimetric Evaluation Scale
Time frame: measured at 6 weeks
validated quality-of-life instrument that is used to assess facial impairment and disability after facial paralysis.
-
Modified Facial Clinimetric Evaluation Scale
Time frame: measured at 3 months
validated quality-of-life instrument that is used to assess facial impairment and disability after facial paralysis.
-
Modified Facial Clinimetric Evaluation Scale
Time frame: measured at 6 months
validated quality-of-life instrument that is used to assess facial impairment and disability after facial paralysis.
-
Modified Facial Clinimetric Evaluation Scale
Time frame: measured at 12 months
validated quality-of-life instrument that is used to assess facial impairment and disability after facial paralysis.
-
Modified Facial Clinimetric Evaluation Scale
Time frame: measured at 18 months
validated quality-of-life instrument that is used to assess facial impairment and disability after facial paralysis.
-
Modified Facial Clinimetric Evaluation Scale
Time frame: measured at 24 months
validated quality-of-life instrument that is used to assess facial impairment and disability after facial paralysis.
-
Facial Disability Index
Time frame: measured at 6 weeks
a disease-specific, self-report instrument for the assessment of disabilities of patients with facial nerve disorders
-
Facial Disability Index
Time frame: measured at 3 months
a disease-specific, self-report instrument for the assessment of disabilities of patients with facial nerve disorders
-
Facial Disability Index
Time frame: measured at 6 months
a disease-specific, self-report instrument for the assessment of disabilities of patients with facial nerve disorders
-
Facial Disability Index
Time frame: measured at 12 months
a disease-specific, self-report instrument for the assessment of disabilities of patients with facial nerve disorders
-
Facial Disability Index
Time frame: measured at 18 months
a disease-specific, self-report instrument for the assessment of disabilities of patients with facial nerve disorders
-
Facial Disability Index
Time frame: measured at 24 months
a disease-specific, self-report instrument for the assessment of disabilities of patients with facial nerve disorders
-
SF-36 Health Survey
Time frame: measured at 6 weeks
a set of generic, coherent, and easily administered quality-of-life measures
-
SF-36 Health Survey
Time frame: measured at 3 months
a set of generic, coherent, and easily administered quality-of-life measures
-
SF-36 Health Survey
Time frame: measured at 6 months
a set of generic, coherent, and easily administered quality-of-life measures
-
SF-36 Health Survey
Time frame: measured at 12 months
a set of generic, coherent, and easily administered quality-of-life measures
-
SF-36 Health Survey
Time frame: measured at 18 months
a set of generic, coherent, and easily administered quality-of-life measures
-
SF-36 Health Survey
Time frame: measured at 24 months
a set of generic, coherent, and easily administered quality-of-life measures
Sponsors and collaborators
Lead sponsor
Methodist Health System
Other
Registry information
Important dates
- Study start
- 2014
- Primary completion
- 2021
- Study completion
- 2021
- First posted
- Nov 11, 2021
- Registry last updated
- Mar 23, 2026
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Completed
Face Transplantation
NCT01140087
Transplantation: Facial Transplantation
Baltimore, Maryland, United States
View Trial Details